@Bangkoknights,
A couple of points:
1. The liquidity can change quickly, as FRE has demonstrated in the past. Over the last 3 years we've had more than 30 days where daily trading exceeded 1 million shares, and as recently as April this year we traded 9 million shares in one day. The trading is there when there's newsflow - and we have a good newsflow runway in front of us in 2025, as I indicated in my recent video. The shares are not so tightly held that it constrains liquidity. The top 10 account for 49% of shares, but there are more than 4,000 shareholders holding the other 51% or 107 million shares.
2. Let's not be too quick to judge us based on short-term sales: We are a drug development company in the early stages of introducing a novel product that has high potential but a longish runway to achieving its full sales potential. Yes, the quarterlies should give an early sign of emerging trends. As mentioned previously here (my post 1/11/24), our 30 September quarterly reported sales of $17k, which were based on online sales alone; with the HCP marketing and Guardian deal in Singapore, we should expect to see a different picture in the December quarterly and beyond.
Finally, Merry Christmas and thank you for observing that we are a very undervalued stock with huge potential, and that you are positive about the future of FRE.
Peter Molloy
